Clinical trials: randomisation, blinding and intention-to-treat

Problem

Clinical trials are often considered the strongest design for evaluating interventions, but their strength depends on careful design and analysis. Students may know that randomised trials are important but may not understand why randomisation, allocation concealment, blinding and intention-to-treat analysis matter. Without these principles, treatment comparisons can be biased even when the study looks formal and statistical.

• Randomisation is described but not understood.
• Allocation concealment is confused with blinding.
• Blinding is ignored when outcomes are subjective.
• Participants who do not follow treatment are removed from analysis without thought.
• Per-protocol and intention-to-treat analyses are confused.
• Baseline imbalance is overinterpreted after randomisation.
• Trial results are discussed without considering bias and adherence.

Intuition

A clinical trial tries to compare what happens under different interventions. Randomisation aims to create groups that are similar on average, including both known and unknown prognostic factors. Allocation concealment prevents selection bias before treatment assignment. Blinding reduces performance and measurement bias after assignment. Intention-to-treat analysis preserves the benefit of randomisation by analysing participants according to their assigned group.

• Randomisation reduces confounding by design.
• Allocation concealment protects the assignment process.
• Blinding reduces bias in behaviour, care and outcome assessment.
• Intention-to-treat preserves the original randomised comparison.
• Per-protocol analysis estimates effects among those who followed the protocol but may be biased.
• Adherence and dropout affect interpretation.

Method

A good trial report should describe the intervention, comparator, eligibility criteria, randomisation process, concealment, blinding, outcome definitions and analysis population. The primary analysis is often intention-to-treat, especially for superiority trials, because it maintains comparability created by randomisation. Additional analyses may explore adherence or protocol effects but should be clearly labelled.

• Step 1: Define the trial population and eligibility criteria.
• Step 2: Define the intervention and comparator.
• Step 3: Define the primary outcome and follow-up time.
• Step 4: Describe the randomisation method.
• Step 5: Describe allocation concealment.
• Step 6: State who was blinded: participants, clinicians, assessors or analysts.
• Step 7: Define the intention-to-treat population.
• Step 8: Report adherence, deviations and missing outcome data.
• Step 9: Analyse participants according to assigned group for ITT.
• Step 10: Discuss sensitivity or per-protocol analyses separately.

Working

Suppose a trial randomises patients to a new treatment or standard care. Some patients assigned to the new treatment do not take it, and some in standard care seek treatment elsewhere. An intention-to-treat analysis still compares patients according to their original assigned groups. This may estimate the effect of offering the treatment strategy in real practice, while preserving the original randomised comparison.

• Randomisation occurs before treatment begins.
• Allocation concealment prevents recruiters from predicting the next assignment.
• Blinding prevents expectations from influencing behaviour or assessment.
• ITT includes participants in the groups to which they were randomised.
• Per-protocol analysis includes only those who followed the protocol.
• As-treated analysis compares participants according to treatment actually received.
• Per-protocol and as-treated analyses can be affected by post-randomisation selection.

Limitations

Randomised trials can still have problems. Poor allocation concealment can introduce selection bias. Lack of blinding can affect subjective outcomes. Missing outcome data can bias results. Non-adherence can dilute treatment effects. Small trials may have baseline imbalance by chance. Trial populations may also be narrower than real-world populations, limiting generalisability.

• Randomisation does not guarantee perfect balance in small samples.
• Lack of allocation concealment can undermine randomisation.
• Blinding may be impossible for some interventions.
• Missing outcomes can threaten validity.
• Non-adherence can complicate interpretation.
• Strict eligibility criteria can limit generalisability.
• Industry sponsorship or selective reporting may affect credibility.

Discussion

A strong clinical trial interpretation should discuss the design features that protect against bias and the practical issues that remain. Students should distinguish efficacy under ideal adherence from effectiveness in real-world implementation. They should also interpret treatment effects with confidence intervals and clinical relevance, not only p-values.

• Explain how randomisation supports fair comparison.
• Mention allocation concealment if reported.
• Discuss blinding and outcome assessment.
• Report adherence and missing data.
• Interpret ITT results as the main randomised comparison.
• Discuss clinical importance as well as statistical significance.
• Comment on generalisability to real patients or settings.

How this connects to learning

Use the guide as a bridge between theory and application.

A resource guide should not replace a full course or live teaching session. Instead, it helps you organise your thinking. Use it to identify what you understand, what feels unclear, and what questions you should ask before applying a method to real data.